Effect of Anti-IgE in Chronic Urticaria
Part of paid clinical trials in Baltimore, Maryland.
- Sponsor
- Johns Hopkins University
- Study ID
- NCT00130234
- Phase
- PHASE2
- Status
- Completed
Conditions
- Urticaria
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Xolair® (Omalizumab) — DRUG
Study Details
This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.
Key Dates
- Start date
- Nov 30, 2004
- Status verified
- May 2008
- Primary completion
- Sep 30, 2007
- Completion
- Sep 30, 2007
Study Design
- Enrollment
- 20 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Johns Hopkins Asthma and Allergy Center | Baltimore | Maryland | 21224-6821 | - |
Find similar trials in Baltimore, MD
By research site